Teva Pharmaceutical Industries (TEVA) vs Zoetis (ZTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Teva Pharmaceutical Industries (TEVA) has outperformed Zoetis (ZTS) over the past year, gaining 95.2% versus a loss of 49.9%. Over five years, TEVA leads with a +304.8% price change compared with -64.6% for ZTS. Teva Pharmaceutical Industries is the larger company by market cap ($45.78 billion vs $30.20 billion), about 1.5 times the size.
On valuation, Zoetis trades at a lower forward P/E (11.2x vs 12.7x for Teva Pharmaceutical Industries). Zoetis pays a dividend yielding 2.82%, while Teva Pharmaceutical Industries does not currently pay one. Zoetis converts more of its revenue into profit, with a net margin of 28.2% versus 8.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TEVA | ZTS |
|---|---|---|
| Share price | $39.25 | $73.08 |
| Market cap | $45.78B | $30.20B |
| 1-day change | +0.18% | +2.14% |
| YTD return | +25.54% | -43.13% |
| 1-year return | +95.22% | -49.88% |
| 5-year return | +304.75% | -64.62% |
| P/E ratio (TTM) | 65.42 | 12.02 |
| Forward P/E | 12.70 | 11.17 |
| EPS (TTM) | $0.60 | $6.08 |
| Dividend yield | 0.00% | 2.82% |
| Annual dividend | $0.00 | $2.06 |
| Revenue (latest FY) | $17.26B | $9.47B |
| Revenue growth (YoY) | +4.32% | +2.28% |
| Net income (latest FY) | $1.41B | $2.67B |
| Gross margin | 51.79% | 71.84% |
| Operating margin | 12.50% | — |
| Net margin | 8.17% | 28.23% |
| 52-week high | $40.79 | $148.30 |
| 52-week low | $18.83 | $68.77 |
| Distance from 52-week high | -3.78% | -50.72% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +15.41% | +31.36% |
| Average volume | 5.29M | 5.45M |
| Shares outstanding | 1.17B | 413.22M |
| Employees | 31,173 | 14,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TEVA has outperformed ZTS by 145.1 percentage points over the past year.
- Teva Pharmaceutical Industries trades at a higher earnings multiple (65.4x vs 12.0x trailing P/E).
- Zoetis offers a meaningfully higher dividend yield (2.82% vs 0.00%).
- Zoetis is more profitable, keeping 28.2 cents of every revenue dollar as net income versus 8.2 cents for Teva Pharmaceutical Industries.
About Teva Pharmaceutical Industries
TEVA stock →Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Health Care · Biotechnology: Pharmaceutical Preparations · 31,173 employees
About Zoetis
ZTS stock →Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 14,500 employees
TEVA vs ZTS FAQ
Which is bigger, Teva Pharmaceutical Industries or Zoetis?
Teva Pharmaceutical Industries (TEVA) is larger, with a market capitalization of $45.78B compared with $30.20B for Zoetis (ZTS).
Which stock has performed better over the past year, TEVA or ZTS?
TEVA returned +95.22% over the past 12 months, compared with -49.88% for ZTS (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, TEVA or ZTS?
ZTS has the lower trailing P/E at 12.0, versus 65.4 for TEVA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Teva Pharmaceutical Industries or Zoetis?
Zoetis pays a dividend yielding 2.82%, while Teva Pharmaceutical Industries does not currently pay a regular dividend.
Are Teva Pharmaceutical Industries and Zoetis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.